Combining immunotherapy and anticancer agents: The right path to achieve cancer cure?

Annals of Oncology

Volumn 26, Issue 9, 2015, Pages 1813-1823

  Apetoh, L ^a,b,c   Ladoire, S ^a,b,c   Coukos, G ^d   Ghiringhelli, François ^a,b,c  

^a Chu   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Anticancer immunity; CD4 T cells; CD8 T cells; Chemotherapy; Immunomodulation; Radiotherapy

Indexed keywords

AGATOLIMOD; BCG VACCINE; BRENTUXIMAB VEDOTIN; CANCER VACCINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DABRAFENIB; DACARBAZINE; DENDRITIC CELL VACCINE; FRESOLIMUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMIQUIMOD; IPILIMUMAB; LENALIDOMIDE; NAVELBINE; NIVOLUMAB; PACLITAXEL; PEPTIDE VACCINE; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 21; RITUXIMAB; SUNITINIB; TICILIMUMAB; TRAMETINIB; TRASTUZUMAB; UNINDEXED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE DISEASE; GASTROINTESTINAL DISEASE; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LEUKEMIA; LIVER DISEASE; LYMPHOMA; MELANOMA; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; NEOPLASM; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN DISEASE; SKIN METASTASIS; SMALL CELL LUNG CANCER; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASM METASTASIS; NEOPLASMS; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASM METASTASIS; NEOPLASMS;

EID: 84937246543     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv209     Document Type: Review

References (167)

1. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-360.
2. Wimmer CD, Angele MK, Schwarz B et al. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients. Transpl Int 2013; 26: 999-1006.
3. Robbins HA, Pfeiffer RM, Shiels MS et al. Excess Cancers Among HIV-Infected People in the United States. J Natl Cancer Inst 2015; 107.
4. Shin M, Moon HH, Kim JM et al. Comparison of the incidence of de novo malignancy in liver or kidney transplant recipients: analysis of 2673 consecutive cases in a single center. Transplant Proc 2013; 45: 3019-3023.
5. Salavoura K, Kolialexi A, Tsangaris G, Mavrou A. Development of cancer in patients with primary immunodeficiencies. Anticancer Res 2008; 28: 1263-1269.
6. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298-306.
7. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213.
8. Apetoh L, Smyth MJ, Drake CG et al. Consensus nomenclature for CD8 T cell phenotypes in cancer. Oncoimmunology 2015; 4, doi: 10.1080/2162402X.2014.998538.
9. Andersen MH, Sorensen RB, Schrama D et al. Cancer treatment: the combination of vaccination with other therapies. Cancer Immunol Immunother 2008; 57: 1735-1743.
10. Menard C, Martin F, Apetoh L et al. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 2008; 57: 1579-1587.
11. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8: 59-73.
12. Yu B, Kusmartsev S, Cheng F et al. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res 2003; 9: 285-294.
13. Weiner HL, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 2002; 8: 142-154.
14. Javeed A, Ashraf M, Riaz A et al. Paclitaxel and immune system. Eur J Pharm Sci 2009; 38: 283-290.
15. Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059.
16. Ghiringhelli F, Apetoh L, Tesniere A et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-1178.
17. Tesniere A, Schlemmer F, Boige V et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29: 482-491.
18. Lake RA, Robinson BW. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 2005; 5: 397-405.
19. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19: 997-1008.
20. Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013; 39: 49-60.
21. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
22. Kirkwood JM, Butterfield LH, Tarhini AA et al. Immunotherapy of cancer in 2012. CA Cancer J Clin 2012; 62: 309-335.
23. Schadendorf D, Ugurel S, Schuler-Thurner B et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006; 17: 563-570.
24. Wimmers F, Schreibelt G, Skold AE et al. Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets. Front Immunol 2014; 5: 165.
25. Carreno BM, Magrini V, Becker-Hapak M et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015; 348: 803-808.
26. Mitchison NA. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med 1955; 102: 157-177.
27. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854.
28. Kershaw MH, Westwood JA, Parker LL et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006; 12: 6106-6115.
29. Lamers CH, Sleijfer S, Vulto AG et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006; 24: e20-e22.
30. Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.
31. Porter DL, Levine BL, Kalos M et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-733.
32. Maude SL, Frey N, Shaw PA et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507-1517.
33. Perna SK, De Angelis B, Pagliara D et al. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res 2013; 19: 106-117.
34. Klebanoff CA, Finkelstein SE, Surman DR et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 2004; 101: 1969-1974.
35. Hoyos V, Savoldo B, Quintarelli C et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010; 24: 1160-1170.
36. Conlon KC, Lugli E, Welles HC et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-inhuman clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 2015; 33: 74-82.
37. Wang G, Tschoi M, Spolski R et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 2003; 63: 9016-9022.
38. Zeng R, Spolski R, Finkelstein SE et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 2005; 201: 139-148.
39. Hinrichs CS, Spolski R, Paulos CM et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 2008; 111: 5326-5333.
40. Singh H, Figliola MJ, Dawson MJ et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 2011; 71: 3516-3527.
41. Vegran F, Berger H, Boidot R et al. The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nat Immunol 2014; 15: 758-766.
42. Petrella TM, Tozer R, Belanger K et al. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol 2012; 30: 3396-3401.
43. Shankaran V, Ikeda H, Bruce AT et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-1111.
44. Allison JP, Krummel MF. The Yin and Yang of T cell costimulation. Science 1995; 270: 932-933.
45. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736.
46. Hodi FS, Butler M, Oble DA et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008; 105: 3005-3010.
47. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
48. Zha Y, Blank C, Gajewski TF. Negative regulation of T-cell function by PD-1. Crit Rev Immunol 2004; 24: 229-237.
49. Latchman Y, Wood CR, Chernova T et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-268.
50. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
51. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800.
52. Iwai Y, Ishida M, Tanaka Y et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293-12297.
53. Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-571.
54. Ribas A, Hodi FS, Callahan M et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368: 1365-1366.
55. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133.
56. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
57. Sherrill B, Wang J, Kotapati S, Chin K. Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma. Br J Cancer 2013; 109: 8-13.
58. Le DT, Lutz E, Uram JN et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013; 36: 382-389.
59. Santegoets SJ, Stam AG, Lougheed SM et al. T cell profiling reveals high CD4+ CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother 2013; 62: 245-256.
60. Kwek SS, Dao V, Roy R et al. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol 2012; 189: 3759-3766.
61. Reck M, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013; 24: 75-83.
62. Millward M, Underhill C, Lobb S et al. Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. Br J Cancer 2013; 108: 1998-2004.
63. Weber JS, Kudchadkar RR, Yu B et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J Clin Oncol 2013; 31: 4311-4318.
64. Zhu C, Anderson AC, Schubart A et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6: 1245-1252.
65. Sakuishi K, Apetoh L, Sullivan JM et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207: 2187-2194.
66. Fourcade J, Sun Z, Benallaoua M et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010; 207: 2175-2186.
67. Fourcade J, Sun Z, Pagliano O et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(+) T cells induced by melanoma vaccines. Cancer Res 2014; 74: 1045-1055.
68. Li SY, Liu Y. Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137. Clin Pharmacol 2013; 5: 47-53.
69. Vonderheide RH, Burg JM, Mick R et al. Phase I study of the CD40 agonist antibody CP-870, 893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2013; 2: e23033.
70. Brignone C, Escudier B, Grygar C et al. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 2009; 15: 6225-6231.
71. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol 2015.
72. Kong YC, Flynn JC. Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1. Front Immunol 2014; 5: 206.
73. Downey SG, Klapper JA, Smith FO et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13: 6681-6688.
74. Stone HB, Peters LJ, Milas L. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst 1979; 63: 1229-1235.
75. Lee Y, Auh SL, Wang Y et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009; 114: 589-595.
76. Demaria S, Formenti SC. Role of T lymphocytes in tumor response to radiotherapy. Front Oncol 2012; 2: 95.
77. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013; 105: 256-265.
78. Demaria S, Pilones KA, Vanpouille-Box C et al. The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation. Radiat Res 2014; 182: 170-181.
79. Obeid M, Tesniere A, Ghiringhelli F et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61.
80. Golden EB, Pellicciotta I, Demaria S et al. The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol 2012; 2: 88.
81. Demaria S, Ng B, Devitt ML et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004; 58: 862-870.
82. Postow MA, Callahan MK, Barker CA et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366: 925-931.
83. Matsumura S, Wang B, Kawashima N et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008; 181: 3099-3107.
84. Lugade AA, Sorensen EW, Gerber SA et al. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 2008; 180: 3132-3139.
85. Reits EA, Hodge JW, Herberts CA et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203: 1259-1271.
86. Ruocco MG, Pilones KA, Kawashima N et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest 2012; 122: 3718-3730.
87. Chakraborty M, Abrams SI, Coleman CN et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004; 64: 4328-4337.
88. Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005; 63: 655-666.
89. Chakraborty M, Abrams SI, Camphausen K et al. Irradiation of tumor cells upregulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003; 170: 6338-6347.
90. Hodge JW, Sharp HJ, Gameiro SR. Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. Cancer Biother Radiopharm 2012; 27: 12-22.
91. Newcomb EW, Demaria S, Lukyanov Y et al. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res 2006; 12: 4730-4737.
92. Medina-Echeverz J, Berraondo P. Colon cancer eradication after chemoimmunotherapy is associated with intratumoral emergence of proinflammatory myeloid cells. Oncoimmunology 2012; 1: 118-120.
93. Zhang B, Bowerman NA, Salama JK et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 2007; 204: 49-55.
94. Demaria S, Kawashima N, Yang AM et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005; 11: 728-734.
95. Dewan MZ, Galloway AE, Kawashima N et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009; 15: 5379-5388.
96. Verbrugge I, Hagekyriakou J, Sharp LL et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012; 72: 3163-3174.
97. Chi KH, Liu SJ, Li CP et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 2005; 28: 129-135.
98. Lechleider RJ, Arlen PM, Tsang KY et al. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 2008; 14: 5284-5291.
99. Slovin SF, Higano CS, Hamid O et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013; 24: 1813-1821.
100. Vacchelli E, Eggermont A, Fridman WH et al. Trial watch: immunostimulatory cytokines. Oncoimmunology 2013; 2: e24850.
101. Vacchelli E, Vitale I, Tartour E et al. Trial watch: anticancer radioimmunotherapy. Oncoimmunology 2013; 2: e25595.
102. Vacchelli E, Vitale I, Eggermont A et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013; 2: e25771.
103. Semeraro M, Vacchelli E, Eggermont A et al. Trial watch: lenalidomide-based immunochemotherapy. Oncoimmunology 2013; 2: e26494.
104. Aranda F, Vacchelli E, Eggermont A et al. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2013; 2: e26621.
105. Vacchelli E, Aranda F, Eggermont A et al. Trial watch: tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3: e27048.
106. Aranda F, Vacchelli E, Eggermont A et al. Trial watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3: e27297.
107. Vacchelli E, Aranda F, Eggermont A et al. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2014; 3: e27878.
108. Aranda F, Vacchelli E, Obrist F et al. Trial watch: toll-like receptor agonists in oncological indications. Oncoimmunology 2014; 3: e29179.
109. Vacchelli E, Aranda F, Obrist F et al. Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014; 3: e29030.
110. Vacchelli E, Eggermont A, Sautes-Fridman C et al. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 2013; 2: e24612.
111. Apetoh L, Vegran F, Ladoire S, Ghiringhelli F. Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies. Curr Mol Med 2011; 11: 365-372.
112. Ghiringhelli F, Apetoh L. Enhancing the anticancer effects of 5-fluorouracil: current challenges and future perspectives. Biomed J 2014.
113. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007; 13: 3776-3782.
114. Wheeler CJ, Das A, Liu G et al. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004; 10: 5316-5326.
115. Lesterhuis WJ, Punt CJ, Hato SV et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 2011; 121: 3100-3108.
116. Ghiringhelli F, Menard C, Puig PE et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641-648.
117. Rettig L, Seidenberg S, Parvanova I et al. Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. Int J Cancer 2011; 129: 832-838.
118. Bolitho P, Street SEA, Westwood JA et al. Perforin-mediated suppression of B-cell lymphoma. Proc Natl Acad Sci USA 2009; 106: 2723-2728.
119. Vincent J, Mignot G, Chalmin F et al. 5-Fluorouracil selectively kills tumorassociated myeloid-derived suppressor cells resulting in enhanced T celldependent antitumor immunity. Cancer Res 2010; 70: 3052-3061.
120. Ko HJ, Kim YJ, Kim YS et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 2007; 67: 7477-7486.
121. Suzuki E, Kapoor V, Jassar AS et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11: 6713-6721.
122. Serrano A, Tanzarella S, Lionello I et al. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-20-deoxycytidine treatment. Int J Cancer 2001; 94: 243-251.
123. Nowak AK, Lake RA, Marzo AL et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than crosstolerizing host tumor-specific CD8 T cells. J Immunol 2003; 170: 4905-4913.
124. Tong Y, Song W, Crystal RG. Combined intratumoral injection of bone marrowderived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res 2001; 61: 7530-7535.
125. Ramakrishnan R, Assudani D, Nagaraj S et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010; 120: 1111-1124.
126. Ganss R, Ryschich E, Klar E et al. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 2002; 62: 1462-1470.
127. Shrimali RK, Yu Z, Theoret MR et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70: 6171-6180.
128. Ding ZC, Blazar BR, Mellor AL et al. Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype. Blood 2010; 115: 2397-2406.
129. Kaech SM, Tan JT, Wherry EJ et al. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003; 4: 1191-1198.
130. Zhang L, Dermawan K, Jin M et al. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin Immunol 2008; 129: 219-229.
131. Yang S, Haluska FG. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzymeand Fas-mediated pathways. J Immunol 2004; 172: 4599-4608.
132. Nistico P, Capone I, Palermo B et al. Chemotherapy enhances vaccineinduced antitumor immunity in melanoma patients. Int J Cancer 2009; 124: 130-139.
133. Nencioni A, Beck J, Werth D et al. Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res 2007; 13: 3933-3941.
134. Triozzi PL, Aldrich W, Achberger S et al. Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice. Cancer Immunol Immunother 2012; 61: 1441-1450.
135. Wolf AM, Wolf D, Rumpold H et al. The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci USA 2005; 102: 13622-13627.
136. Wilmott JS, Long GV, Howle JR et al. Selective BRAF inhibitors induce marked Tcell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18: 1386-1394.
137. Boni A, Cogdill AP, Dang P et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70: 5213-5219.
138. Hannesdottir L, Tymoszuk P, Parajuli N et al. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol 2013; 43: 2718-2729.
139. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11: 215-233.
140. Adotevi O, Pere H, Ravel P et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010; 33: 991-998.
141. Terme M, Pernot S, Marcheteau E et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2013; 73: 539-549.
142. Ko JS, Zea AH, Rini BI et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15: 2148-2157.
143. Larmonier N, Janikashvili N, LaCasse CJ et al. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL-tumors. J Immunol 2008; 181: 6955-6963.
144. Xin H, Zhang C, Herrmann A et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69: 2506-2513.
145. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51.
146. Amin A, Plimack E, Infante J et al. Nivolumab (N) (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib (S) or pazopanib (P) in patients with metastatic renal cell carcinoma (mRCC). ESMO 2014 2014; Abstract 1052PD.
147. Hamzah J, Jugold M, Kiessling F et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008; 453: 410-414.
148. Huang Y, Yuan J, Righi E et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA 2012; 109: 17561-17566.
149. Matsumoto S, Batra S, Saito K et al. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res 2011; 71: 6350-6359.
150. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-3947.
151. Bibeau F, Lopez-Crapez E, Di Fiore F et al. Impact of Fc{gamma}RIIa-Fc{gamma} RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 1122-1129.
152. Musolino A, Naldi N, Bortesi B et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789-1796.
153. Park S, Jiang Z, Mortenson ED et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18: 160-170.
154. Stagg J, Loi S, Divisekera U et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 2011; 108: 7142-7147.
155. Kohrt HE, Houot R, Weiskopf K et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012; 122: 1066-1075.
156. Disis ML, Wallace DR, Gooley TA et al. Concurrent trastuzumab and HER2/neuspecific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009; 27: 4685-4692.
157. Benavides LC, Gates JD, Carmichael MG et al. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2009; 15: 2895-2904.
158. Norell H, Poschke I, Charo J et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med 2010; 8: 53.
159. Emens L, Gupta R, Petrik S et al. A feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2+ metastatic breast cancer. ASCO Meeting Abstr 2011; 29(15 Suppl): 2535.
160. Disis ML, Dang Y, Bates N. Phase II study of a HER-2/Neu (HER2) intracellular domain (ICD) given concurrently with trastuzumab in patients with newly diagnosed advanced stage breast cancer. Cancer Res 2010; 69(24 Suppl): 5102.
161. Milani A, Sangiolo D, Montemurro F et al. Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol 2013; 24: 1740-1748.
162. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010; 107: 4275-4280.
163. Woo SR, Turnis ME, Goldberg MV et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012; 72: 917-927.
164. Lynch TJ, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012; 30: 2046-2054.
165. Maio M, Di Giacomo AM, Robert C, Eggermont AM. Update on the role of ipilimumab in melanoma and first data on new combination therapies. Curr Opin Oncol 2013; 25: 166-172.
166. Brignone C, Gutierrez M, Mefti F et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 2010; 8: 71.
167. Demaria S, Pilones KA, Formenti SC, Dustin ML. Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment. Oncoimmunology 2013; 2: e23127.